Ankyra Therapeutics, Inc.
Localized cytokine cancer therapeutics that prime systemic adaptive immune response
- Sector
- Biotech
- Headquarters
- BOSTON, MA
- Founded
- 2019
- Latest Form D
- $45M, Sep 2021
- Total capital
- $59.5M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $59.5M
- 2 Form D · last Sep 2021
- 62 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 1
- 12 pending · first 2025
- Rank in peer group#481 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 2nd filing$45M
- Private capital raisedForm D · SEC · 1st filing$14.5M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#481 · top 33%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Ajay RoyanDirectorNamed in SEC Form D filings
- Philip FerneauDirectorNamed in SEC Form D filings
- Terrance McGuireDirectorNamed in SEC Form D filings
- Tillman GerngrossExecutive Officer, DirectorNamed in SEC Form D filings
What it has protected
USPTO · 1 granted of 13- PendingFusion PolypeptidesUSPTOApplication 19352767
- PendingFusion Polypeptides And Formulations ThereofUSPTOApplication 19128365
- GrantedFusion Polypeptides Comprising Interleukin 12 And A Metal-hydroxide Binding PolypeptideUSPTOUS 12,454,695
Show all 13 patent records
- Fusion PolypeptidesFeb 5, 2026 · Application 19352767Pending
- Fusion Polypeptides And Formulations ThereofNov 6, 2025 · Application 19128365Pending
- Fusion Polypeptides Comprising Interleukin 12 And A Metal-hydroxide Binding PolypeptideOct 28, 2025 · US 12,454,695Granted
- Fusion PolypeptidesOct 23, 2025 · Application 19251378Pending
- FormulationsApplication 63424013Pending
- ManufacturingApplication 63424047Pending
- Fusion PolypeptidesApplication PCTUS2022027617Pending
- Fusion PolypeptidesApplication 63184620Pending
- Tnf Receptor Superfamily Agonist Fusion PolypeptidesApplication PCTUS2025054560Pending
- Methods Of Making Fusion PolypeptidesApplication 19128435Pending
- Tnf Receptor Superfamily Agonist Fusion PolypeptidesApplication 63718204Pending
- Fusion Polypeptides And Formulations ThereofApplication PCTUS2023036996Pending
- Methods Of Making Fusion PolypeptidesApplication PCTUS2023037011Pending
Related companies, and why
- Ernexa Therapeutics Inc.Similar federal contract value in Biotech · null in contracts
- KAZIA THERAPEUTICS LTDSimilar federal contract value in Biotech · null in contracts
- Abata TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Checkpoint Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- Longboard Pharmaceuticals, Inc.Similar federal contract value in Biotech · null in contracts
- Alpheus MedicalSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .